Frontlight ResearchEarly access
Taking people in SwedenPhase 1/2
Tests histamine and low-dose interleukin-2 around surgery for pancreatic cancer
Tests two drugs given before and after surgery in adults with pancreatic cancer.
Key facts
- Who runs it
- Vaestra Goetalandsregionen
- Where
- Goteborg, SwedenSee the site
- Trial code
- Registry title
- PANCEP-1
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 50 people, planned
- Started
- 2 Sept 2025
- Expected to end
- 1 Jan 2029
- Type of study
- Interventional
- Record updated
- 17 May 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with pancreatic or periampullary cancer that can be removed by surgery and who are fit for pancreatic surgery.
- Age
- Over 18 years
- Sex
- Men and women
- Disease stage
- Primary pancreatic or periampullary cancer that can be removed by surgery, confirmed by scans and/or cell tests. Pancreatic ductal adenocarcinoma, ampullary carcinoma and cholangiocarcinoma are the most common forms; other rare forms may also join.
- Earlier treatment
- Current treatment with medicines that change the immune system, such as corticosteroids, is not allowed.
Main reasons for not taking part
- Serious heart disease, severe blood pressure problems or serious uncontrolled heart rhythm problems
- Heart attack within the past 6 months
- Uncontrolled seizures, severe nervous system disorders or psychiatric problems that affect following the protocol
- Current active stomach ulcer or current asthma
- Women who can have children and do not agree to use effective contraception
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients must give written informed consent prior to initiation of therapy, in keeping with the policies of the institution
- Patient is a male or female age >18
- By the surgeons evaluation fit for pancreatic surgery
- Subjects must have radiologic, and/or cytologic confirmation of primary resectable pancreatic or periampullary cancer. Pancreatic ductal adenocarcinoma, ampullary carcinoma and cholangiocarcinoma are the most common forms, but also other rare forms of pancreatic and periampullary cancer may be included
Who cannot take part
- Ongoing treatment with immunomodulating medication, i.e. corticosteroids
- Class III or IV cardiac disease, hypotension or severe hypertension, vasomotor instability, serious or uncontrolled cardiac dysrhythmias (including ventricular arrhythmias) at any time, acute myocardial infarction within the past 6 months, active uncontrolled angina pectoris or symptomatic arteriosclerotic blood vessel disease
- History of uncontrolled seizures, severe central nervous system disorders, or psychiatric disability thought to be clinically significant in the opinion of the Investigator and adversely affecting compliance to protocol
- Ongoing active peptic ulcer
- Any other condition or symptoms preventing the patient from entering the study, according to the PI's judgement
- A woman of childbearing potential (WOCBP) must agree to comply with using an effective contraceptive method for the duration of the treatment (a WOCBP is a sexually mature woman who is not surgically sterile or has not been naturally postmenopausal for at least 12 consecutive months). Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception. Highly effective methods of contraception have a failure rate of < 1% when used consistently and correctly. Local laws and regulations may require use of alternative and/or additional contraception methods. One of the highly effective methods of contraception listed below is required during study duration and until the end of relevant systemic exposure, defined as 5 months after the end of study treatment
- Ongoing asthma
Where in Sweden
- Sahlgrenska University Hospital-Vastra GotalandsregionenGoteborg, SwedenTaking people
About the trial
What the trial wants to find out
To assess the frequency and extent of adverse events associated with the therapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A phase I/II trial of peri- and postoperative treatment with histamine dihydrocloride and low-dose interleukin-2 in patients with primary resectable pancreatic cancer.
- Plain-language title
- Tests histamine and low-dose interleukin-2 around surgery for pancreatic cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 17 May 2024